Estamos trabajando para incorporar este artículo al repositorio
Consulte la política de Acceso Abierto del editor


Heparin Cofactor II (HCII) is a glycoprotein in human plasma which inactivates thrombin rapidly in the presence of dermatan sulfate. Inhibition occurs by formation of a stable equimolar complex between HCII and thrombin. HCII association with thrombotic events has not always been observed, thus decreased HCII does not appear to be a strong risk factor for thromboembolic events. Reduced HCII levels have been detected in different clinical conditions, such as hepatic failure, disseminated intravascular coagulation, thalasemina, sickle cell anemia. Increased physiological levels have been found in pregnant women and oral contraception. In our laboratory, we measured HCII plasmatic levels in the normal Buenos Aires city population and in patients under different clinical conditions, such as sepsis, diabetis, burns, oral anticoagulation and in patients treated with heparin, hyperhomcysteinemia in whom septic and diabetic patients showed decreased values. HCII thrombin inhibition possibly takes place in extravascular sites where dermatan sulfate is present. HCII activity would be important in the regulation of wound healing, inflammation, or neuronal development.


Documento: Artículo
Título:Heparin cofactor II, a thrombin inhibitor with a still unclarified physiologic role
Autor:Rossi, E.B.; Duboscq, C.L.; Kordich, L.C.
Filiación:Depto. de Quim. Biológica, Ciudad Universitaria, Universidad de Buenos Aires, 4to piso, Pabellón II, 1428 Buenos Aires, Argentina
Palabras clave:Dermatan sulfate; Heparin cofactor II; Thrombin; dermatan sulfate; heparin; heparin cofactor; thrombin; anticoagulation; article; burn; human; hyperhomocysteinemia; liver failure; nerve cell differentiation; risk factor; sepsis; sickle cell anemia; thalassemia; thromboembolism; wound healing; Coagulation Protein Disorders; Dermatan Sulfate; Heparin Cofactor II; Humans; Reference Values; Serine Proteinase Inhibitors; Thrombin
Página de inicio:95
Página de fin:104
Título revista:Medicina
Título revista abreviado:Medicina (Argentina)
CAS:Dermatan Sulfate, 24967-94-0; Heparin Cofactor II, 81604-65-1; Serine Proteinase Inhibitors; Thrombin, EC


  • Furie, B., Furie, B.C., The molecular bases of blood coagulation (1991) Hematologyc Basic Principles and Practice. 3rd Ed., p. 1213. , Hoffman R, Benz E, Shattil S, Furie B, Cohen H Ed. London: Churchill
  • Sánchez Avalos, J.C., Fisiología de la hemostasia. En manual de hemostasia y trombosis (1990) Buenos Aires, pp. 3-17. , Kordich L, et al. (eds)
  • Hemker, H.C., Thrombin generation, an essential step an haemostasis and thrombosis (1993) Haemostasis and Thrombose, pp. 477-490. , A. Bloom et al (eds). Edinburg: Churchill Livingstone
  • Fenton J.W. II, Thrombin functions and antithrombotic intervention (1995) Thromb Haemost, 74 (1), pp. 493-498
  • Guillin, M.C., Bezeaud, A., Bouton, M.C., Jandrot-Perrus, M., Thrombin specificity (1995) Thromb Haemost, 74 (1), pp. 129-133
  • Brinkhous, K.M., Smith, H.P., Warner, E.D., Seegers, W.H., The inhibition of blood clotting. An unidentified substance which acts in conjunction with heparin to prevent conversion of prothrombin to thrombin (1939) Am J Physiol, 125, pp. 683-687
  • Abildgaard, U., Purification of two progressive antithrombins of human plasma (1967) Scand J Lab Clin Invest, 19, pp. 190-195
  • Briginshaw, G.F., Shanberge, U.N., Identification of two distinct heparin cofactors in human plasma. Separation and partial purification (1974) Arch Biochem Biophys, 161, pp. 683-690
  • Tollefsen, D.M., Blank, M.K., Detection of a new Heparin-dependent inhibitor of Thrombin in human plasma (1981) J Clin. Invest, 68, pp. 589-596
  • Tollefsen, D.M., Majerus, D.W., Blank, M.K., Heparin cofactor II. Purification and properties of a heparin dependent inhibitor of thrombin in human plasma (1982) J Biol Chem, 257, pp. 2162-2169
  • Blinder, M.A., Marasa, J.C., Reynolds, C.H., Deaven, L.L., Tollefsen, D.M., Heparin Cofactor II: CDNA sequence, chromosome localisation, restriction fragment length polymorphism, and expression in Escherichia coli (1988) Biochemistry, 27, pp. 752-759
  • Sié, P., Dupouy, D., Pichon, J., Boneu, B., Turnover study of Heparin Cofactor II in healthy man (1985) Thromb Haemost, 54 (3), pp. 635-638
  • Herzog, R., Lutz, S., Blin, N., Marasa, J.C., Blinder, M.A., Tollefsen, D.M., Complete nucleotide sequence of the gene for human heparin cofactor II and mapping to chromosomal band 22q11 (1991) Biochemistry, 30, pp. 1350-1357
  • Derechin, V.M., Blinder, M.A., Tollefsen, D.M., Substitution of arginine for leucine 444 in the reactive site of heparin cofactor II enhances the rate of thrombin inhibition (1990) J Biol Chem, 265, pp. 5623-5628
  • Ragg, H., Ulshofer, T., Gerewitz, J., On the activation of human leuserpin 2. A thrombin inhibitor by glycosaminoglycans (1990) J Biol Chem, 265, pp. 5211-5218
  • Tollefsen, D.M., The interaction of glycosaminoglycans with heparin cofactor II (1994) Annals New York Academy of Sciences, 714, pp. 21-31
  • Church, F.C., Treabor, R.E., Sherrill, G.B., Whinna, H.C., Carboxylate polyanions accelerate inhibition of thrombin by heparin cofactor II (1987) Biochem Biophys Res Commun, 148, pp. 362-368
  • Church, F.C., Pratt, C.W., Treanor, R.E., Whinna, H.C., Antithrombotic action of phosvitin and other phosphate containing polyaniones is mediated by heparin cofactor II (1988) FEBS Lett, 237, pp. 26-30
  • Church, F.C., Meade, J.B., Treanor, R.E., Whinna, H.C., Antithrombin activity of fucoidan: The interaction of fucoidan with heparin cofactor II, antithrombin III, and thrombin (1989) J Biol Chem, 264, pp. 3618-3623
  • Hayakawa, Y., Hayashi, T., Hayashi, T., Niiya, K., Sakuragawa, N., Selective activation of heparin cofactor II by a sulfated polysaccharide isolates from the leaves of Artemisia princeps (1995) Blood Coag Fibrinol, 6, pp. 643-649
  • Tollefsen, D.M., Activation of heparin cofactor II by heparin and dermatan sulfate (1984) Nouv Rev Fr Hematol, 26, pp. 233-237
  • Rydel, T.J., Ravichandran, K.G., Tulinsky, A., Bode, W., Huber, R., Roistsch, C., Fenton J.W. II, The structure of a complex of recombinant hirudin and human alpha thrombin (1990) Science, 249, pp. 277-280
  • Sheehan, J.P., Wu, Q., Tollefsen, D.M., Sadler, J.E., Mutagenesis of thrombin selectively modulates inhibition by serpins Heparin Cofactor II and Antithrombin III (1993) J Biol Chem, 268, pp. 3639-3645
  • Tollefsen, D.M., Insight into the mechanism of action of heparin cofactor II (1995) Thromb Haemost, 74 (5), pp. 1209-1214
  • Sheehan, J.P., Tollefsen, D.M., Sadler, J.E., Heparin Cofactor II is regulated allosterically and not primarily by templates effects: Studies with mutant thrombins and glycosaminoglycans (1994) J Biol Chem, 269, pp. 32747-32751
  • Thumberg, L., Backstrom, G., Lindahl, U., Further characterization of the antithrombin-binding sequence in heparin (1982) Carbohydr Res, 100, pp. 393-410
  • Olson, S.T., Björk, I., Role of protein conformational changes, surface approximation and proteins cofactors in heparinaccelerated antithrombin-proteinase reactions (1992) Heparin and Related Polysaccharides, 313, pp. 155-165. , Lane D.A., Björk I, Lindahl U., eds. New York: Plenum Press
  • Prat, C.W., Whinna, H.C., Church, F.C., A comparation of three heparin-binding serine protease inhibitors (1992) J Biol Chem, 267, pp. 8795-8801
  • Olds, R.J., Lane, D.A., Mille, B., Chowdhury, V., Lay Thein, S., Antithrombin: The principal inhibitor of thrombin (1994) Seminars in Thrombosis and Hemostasis, 20, pp. 353-372
  • Bovill, E.G., Tracy, R.P., Hayes, T.E., Jenny, R.J., Bhushan, F.H., Mann, K.G., Evidence that meizothrombin is an intermediate product in the clotting of whole blood (1995) Arterioscler Thromb Vasc Biol, 12, pp. 754-758
  • Han, J.H., Coté, H.C.F., Tollefsen, D.M., Inhibition of meizothrombin and meizothrombin (desF1) by Heparin Cofactor II (1997) J Biol Chem, 272, pp. 28660-28665
  • Bendayan, P., Boccalon, H., Dupouy, D., Bomeau, B., Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins (1994) Thromb Haemost, 71, pp. 567-582
  • Tollefsen, D.M., Pestka, C.A., Modulation of heparin cofactor II activity by histidinerich glycoprotein and platelet factor 4 (1985) J Clin Invest, 75, pp. 496-501
  • Preissner, K.T., Sie, P., Modulation of heparin cofactor II function by S protein (vitronectin) and formation of a ternary S protein-thfombin-heparin cofactor II complex (1988) Thromb Haemosf, 60 (3), pp. 399-406
  • Kounnas, M.Z., Church, F.C., Argraves, W.S., Strickland, D.K., Cellular internalisation and degradation of Antithrombin III-Thrombin, Heparin Cofactor II-Thrombin, and α1Antytrypsin-Trypsin complexes is mediated by the low density lipoprotein receptor-relates protein (1996) J Biol Chem, 271, pp. 6523-6529
  • De Boer, H.C., Preissner, K.T., Bouma, B.N., De Groot, P.G., Binding of vitronectin-thrombin-antithrombin III complex to human endothelial cells is mediated by the heparin binding site of vitronectin (1992) J Biol Chem, 267, pp. 2264-2268
  • Preissner, K.T., De Boer, H., Pannekoek, H., De Groot, P.G., Thrombin regulation by physiological inhibitors: The role of vitronectin (1996) Seminars in Thrombosis and Hemostasis, 22, pp. 165-172
  • Preissner, K.T., Structure and biological role of vitronectin (1991) Annu Rev Cell Biol, 7, pp. 275-310
  • Liu, L., Dewar, L., Song, Y., Kulczycky, M., Blajchman, M.A., Fenton J.W. II, Inhibition of thrombin by antithrornbin III and heparin cofactor II in vivo (1995) Thromb Haemost, 73 (3), pp. 405-412
  • Linhart, R., Hakim, A., Liu, Kim, Y.S., Fareed, J., Molecular profile and mapping of Dermatan sulfates from different origins (1991) Sem in Thromb and Hemostas, 71, pp. 15-22
  • Hampson, I.N., Gallagher, J.Y., Separation of radiolabelled glycosaminoglycan oligosaccharides by poliacrilamide-gel; electrophoresis (1984) Biochem J, 221, pp. 697-705
  • Delorme, M.A., Saees, N., Sevick, A., Mitchell, L., Berry, L., Johnston, M., Andrew, M., Plasma dermatan sulfate proteoglycan in a patient on chronic hemodialysis (1993) Blood, 82, pp. 3380-3385
  • Andrew, M., Mitchel, L., Berry, L., Paes, B., Delorme, M., Ofosu, F., Burrows, R., Khambalia, B., An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant women and her fetus (1992) J Clin Invest, 89, pp. 321-326
  • Pradoi, P., Meduri, F., Cuppini, S., Toniato, A., Zangrandi, F., Polistena, P., Gianese, F., Maffei Faccioli, A., Dermatan sulfate: A safe approach to prevention of postoperative deep vein thrombosis (1992) Br J Surg, 79, pp. 505-509
  • Agnelli, G., Cosmi, B., Di Filippo, P., Ranucci, V., Veschi, F., Lobgetti, M., Renga, C., A, R., A randomised, double-blind, placebo-controlled trial of dermatan sulfate for prevention of deep vein thrombosis in hip fracture (1992) Thromb Haemost, 67, pp. 203-208
  • Boneu, B., Glycosaminoglycans: Clinical use (1996) Sem in Thromb Hemost, 22, pp. 209-212
  • Sie, P., Dupouy, D., Pichon, J., Boneu, B., Constitutional heparin cofactor II deficiency associated with recurrent thrombosis (1985) Lancet, 2, pp. 414-416
  • Duboscq, C., Quintana, I., Barrios, J., Kordich, L., Heparin Cofactor II in diabetic patients (1994) Blood Coag Fibrinol, 5, pp. 201-204
  • Conard, J., Bara, L., Horellou, M.H., Samama, M.M., Bobine or human thrombin in amidolytic ATIII assays. Infuence of heparin cofactor II (1986) Thromb Res, 41, pp. 873-878
  • Lane, D.A., Mannucci, P.M., Bauer, K.A., Bertina, R.M., Bochkov, N.P., Boulyjenkov, V., Inherited thrombophilia: Part 1 (1996) Thromb Haemost, 76 (5), pp. 651-662
  • Seligsohn, U., Zivelin, A., Thrombophilia as a multigenic disorder (1997) Thromb Haemost, 78, pp. 297-301
  • Tran, T.H., Marbet, G.A., Duckert, F., Association of hereditary heparin cofactor II deficiency with thrombosis (1985) Lancet, 11, pp. 413-414
  • Simioni, P., Lazzaro, A.R., Coser, E., Salmistraro, G., Girolami, A., Hereditary heparin cofactor II deficiency and thrombosis: Report of six patients belonging to two separate kindreds (1990) Blood Coag Fibrinol, 1, pp. 351-356
  • Berina, R.M., Van der Linden, I.K., Engesser, L., Muller, H.P., Brommer, J.P., Hereditary heparin cofactor II deficiency and the risk of development of thrombosis (1987) Thromb Haemost, 57, pp. 196-200
  • Blinder, M., Anderson, T.R., Abildgaard, U., Tollefsen, D.M., Heparin Cofactor II Oslo (1989) The Journal of Biologycal Chemistry, 264, pp. 5128-5133
  • Matsuo, T., Kario, K., Sakamoto, S., Yamada, T., Miki, T., Hirase, T., Hereditary heparin cofactor II deficiency and coronary artery disease (1992) Thromb Res, 65, pp. 495-497
  • Bernardi, F., Legnani, C., Micheletti, F., Lunghi, B., Ferraresi, P., Palareti, G., A Heparin Cofactor II mutation (HCII Rimini) combined with factor V Leiden or type I protein C deficiency in two unrelated thrombophilic subjects (1996) Thromb Haemost, 76 (4), pp. 505-509
  • Tollefsen, D.M., Pestka, C., Heparin Cofactor II activity in patients with disseminated intravascular coagulation and hepatic failure (1985) Blood, 66, pp. 769-774
  • Vinazzer, H., Stocker, K., Heparin Cofactor II: Experimental approach to a new assay and clinical results (1991) Thrombosis Research, 61, pp. 235-241
  • Porter, J.B., Young, L., Mackie, I.J., Marshall, L., Machin, S.J., Sickle cell disorders and chronic intravascular haemolysis are associated with low plasma heparin cofactor II (1993) British Journal of Haematology, 83, pp. 459-465
  • Sandset, P.M., Hellgren, M., Uvebrandt, M., Bergström, H., Extrinsic coagulation pathway inhibitor and heparin cofactor II during normal and hypertensive pregnancy (1989) Thromb Res, 55, pp. 665-670
  • Mackie, I.J., Segal, H., Burren, T., Gallimore, M., Walshe, K.J., Robinson, G., Machin, S.J., Heparin Cofactor II levels are increased by the use of combined oral contraceptives (1990) Blood Coag Fibrinol, 1, pp. 647-651
  • Toulon, P., Lamine, M., Lejev, I., Guez, T., Holleman, M.E., Sereni, D., Sicard, D., Heparin cofactor II deficiency in patients infected with the human inmmunodeficiency virus (1993) Thromb Haemost, 70, pp. 730-735
  • Sie, P., Meguira, B., Boissou, F., Boneu, B., Barthe, P., Plasma Levels of Heparin Cofactor II in Nephrotic Syndrome of Children, , Tesis doctoral de Pierre Sie. Université Paris VII. Uer Medicine St Louis. Lariboisière
  • Toulon, P., Vitoux, J.F., Capron, L., Roncato, M., Fiessinger, J.N., Aiach, M., Heparin Cofactor II in Patients with Deep Venous Thrombosis under Heparin and Oral Anticoagulant Therapy, , Tesis doctoral de Pierre Sie. Université Paris VII. Uer Medicine St Louis. Lariboisière
  • Matsuo, T., Kobayashi, H., Kadowaki, S., Diabetes mellitus as a prethrombotic state: Both heparin cofactor II (HCII) and antithrombin III (ATIII) were depresed in diabetes mellitus (1989) Thromb Haemost, 62, p. 1442. , abstract
  • Recomendación aprobada sobre teoría de los valores de referenda (1988) Acta Bioquímica Clínica Latinoamericana, 22 (3), p. 443
  • Rodeghiero, F., Tosetto, A., The VITA proyect: Population-based distributions of Protein C. Antithrombin III. Heparin cofactor II and Plasminogen relationship with physiological variables and establishment of reference ranges (1996) Thromb Haemost, 76, pp. 226-233
  • Tran, T.H., Duckert, F., Heparin cofactor II determination levels in normal and patients with hereditary antithrombin III deficiency and disseminated intravascular coagulation (1984) Thromb Haemost, 52, pp. 112-116
  • Anderson, T.R., Larsen, M.L., Handeland, G.F., Abildgaard, U., Heparin cofactor II activity in plasma: Application of an automated assay method to the study of a normal adult population (1986) Scand J Haematol, 36, pp. 96-102
  • Abildgaard, U., Larsen, M.L., Assay of dermatan sulfate cofactor (heparin cofactor II) activity in human plasma (1984) Thromb Res, 35, pp. 257-266
  • Toulon, P., Jacquot, C., Capron, L., Frydman, M.O., Vignon, D., Aiach, M., Antithrombin III and Heparin Cofactor II in patients with chronic renal failure undergoing regular hemodialysis (1987) Thromb Haemost
  • Griffith, M.J., Thompson, G.F., McNeely, T.B., Marbet, G.A., White, G.C., Measurement of Heparin Cofactor II levels in human plasma (1984) Circulation, 70, p. 361
  • Duboscq, C., Quintana, I., Rossi, E., Kordich, L., Cofactor II de la heparina, valores de referencia, consumo en presencia de distintos glicosaminoglicanos (1995) Acta Bioquímica Clínica Latinoamericana, 29 (4), pp. 485-492
  • Definition for sepsis an organ failure and guidelines for the use of innovative therapies in sepsis (1992) Chest, 101, p. 1644. , ACCP/SCCM consensus conference
  • Kordich, L., Sassetti, B., Lago, O., Modificación de los factores de coagulación y ATIII por acción de enzimas leucocitarias (1978) Medicina (Buenos Aires), 38, pp. 840-844
  • Sie, P., Dupouy, D., Dol, F., Boneu, B., Inactivation of Heparin Cofactor II by Polymorphonuclear Leukocytes


---------- APA ----------
Rossi, E.B., Duboscq, C.L. & Kordich, L.C. (1999) . Heparin cofactor II, a thrombin inhibitor with a still unclarified physiologic role . Medicina, 59(1), 95-104.
Recuperado de [ ]
---------- CHICAGO ----------
Rossi, E.B., Duboscq, C.L., Kordich, L.C. "Heparin cofactor II, a thrombin inhibitor with a still unclarified physiologic role " . Medicina 59, no. 1 (1999) : 95-104.
Recuperado de [ ]
---------- MLA ----------
Rossi, E.B., Duboscq, C.L., Kordich, L.C. "Heparin cofactor II, a thrombin inhibitor with a still unclarified physiologic role " . Medicina, vol. 59, no. 1, 1999, pp. 95-104.
Recuperado de [ ]
---------- VANCOUVER ----------
Rossi, E.B., Duboscq, C.L., Kordich, L.C. Heparin cofactor II, a thrombin inhibitor with a still unclarified physiologic role . Medicina (Argentina). 1999;59(1):95-104.
Available from: [ ]